What does it mean to #BeFierce? Our new look tells the story

FierceBiotech Logo

A few years ago, one of our Fierce Life Sciences editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked. It was a glancing reference, but the comment stuck, and for good reason. We had never articulated, for ourselves or anyone else, what being Fierce actually meant.

Today, we are. I am pleased to introduce to you a new look for Fierce Life Sciences that exemplifies our bold, forward-thinking approach to everything we do here. It marks a new and improved destination not only for news and analysis you can’t get anywhere else, but for events that delve deeply into the biopharma universe.

Our websites may be most familiar to you as a reader, but our sister company, ExL, has produced a full slate of educational events for years. Now, we’re all Fierce. We’re merging our news and event brands to bring you greater access to information, education, inspiration and new connections.

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

That’s why our new look extends across our websites, newsletters and events—to show the combined might of Fierce Life Sciences. With our coverage from preclinical research to market and beyond, we now reach a community of 500,000 subscribers and attendees.

We’re excited to debut this merger. For an overview of our new brands and offerings, please visit www.fiercelifesciences.com. Take a spin through the sites and let me know what you think.

What isn’t changing? Our commitment to editorial independence and quality, and our engaging, content-driven conferences that attract decisionmakers across the biopharma and healthcare communities. We’re proud to bring you Fierce insights and connections everywhere you need us to be.

As always, thank you for reading and thank you for being a part of the Fierce community. #BeFierce.  – Rebecca Willumson (email | Twitter) 

WeAreFierce

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

The FDA granted an emergency authorization to a portable coronavirus antigen test developed by BD, similar to a rapid flu swab test.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.